{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Honda A"],"funding":["Japan Society for the Promotion of Science"],"pagination":["e075253"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10860085"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(2)"],"pubmed_abstract":["<h4>Introduction</h4>Food allergy affects a large population throughout the world. Recently, oral immunotherapy (OIT) has been reported as an effective treatment for severe food allergy. Although OIT was successful in numerous trials in desensitisation, adverse events including anaphylaxis during OIT frequently occur. Additionally, some patients fail to be desensitised after OIT and the response to treatment is often not sustained. As a further adjunctive therapy to facilitate OIT, the role of biological agents has been identified. For example, efficacy and safety of omalizumab as an adjuvant therapy of OIT has become apparent through some RCTs and observational studies. Interest towards this topic is growing worldwide, and ongoing trials will provide additional data on the biologics in fo"],"journal":["BMJ open"],"pubmed_title":["Efficacy of biological agents combined with oral immunotherapy (OIT) for food allergy: a protocol for a systematic review and meta-analysis."],"pmcid":["PMC10860085"],"funding_grant_id":["KAKENHI(19K03092)"],"pubmed_authors":["Honda A","Okada Y","Matsushita T","Noma H","Kwong J","Hasegawa T","Ota E","Imai T"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of biological agents combined with oral immunotherapy (OIT) for food allergy: a protocol for a systematic review and meta-analysis.","description":"<h4>Introduction</h4>Food allergy affects a large population throughout the world. Recently, oral immunotherapy (OIT) has been reported as an effective treatment for severe food allergy. Although OIT was successful in numerous trials in desensitisation, adverse events including anaphylaxis during OIT frequently occur. Additionally, some patients fail to be desensitised after OIT and the response to treatment is often not sustained. As a further adjunctive therapy to facilitate OIT, the role of biological agents has been identified. For example, efficacy and safety of omalizumab as an adjuvant therapy of OIT has become apparent through some RCTs and observational studies. Interest towards this topic is growing worldwide, and ongoing trials will provide additional data on the biologics in fo","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2026-07-14T22:06:16.511Z","creation":"2025-04-05T11:39:04.278Z"},"accession":"S-EPMC10860085","cross_references":{"pubmed":["38326257"],"doi":["10.1136/bmjopen-2023-075253"]}}